VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder Oct 26, 2017
VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent Regarding Methods of Production for AV-101 Sep 28, 2017
VistaGen Announces Closing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock Sep 6, 2017
VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock Aug 31, 2017
VistaGen Therapeutics Expands VistaStem's Scientific Advisory Board with Appointment of Medicinal Chemistry Expert, David Rotella, PhD Aug 21, 2017
VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update Aug 14, 2017
VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer Aug 8, 2017
VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain Jul 10, 2017
VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update Jun 29, 2017
VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101's Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neuropathic Pain Jun 22, 2017
